Compared with the placebo group , the teriparatide group showed increased LS aBMD ( 6.1 % 1.0 % vs. 2.8 % 1.0 % change from baseline ; P < 0.05 ) and total hip aBMD ( 2.6 % 1.0 % vs. -2.4 % 1.0 % change ; P < 0.001 ) .